Education
About Us
Working with TipRanks
Follow Us
Globus Medical (GMED)
NYSE:GMED
GMED Analyst Ratings
Moderate Buy
10 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GMED Stock 12 Month Forecast
Average Price Target
$98.75
▲(34.06% Upside)
| Highest Price Target$115.00 | Average Price Target$98.75 | Lowest Price Target$82.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Wells Fargo
Reiterated
03/24/25
Truist Financial
Reiterated
03/18/25
Stifel Nicolaus
Reiterated
03/18/25
Morgan Stanley
Reiterated
03/18/25
Needham
Reiterated
03/18/25
Piper Sandler
Reiterated
03/17/25
Roth MKM
Reiterated
03/13/25
RBC Capital
Reiterated
03/11/25
BTIG
Reiterated
02/24/25
JMP Securities
Reiterated
02/24/25
Barclays
$100→$103
Buy
39.83%
Upside
Reiterated
02/21/25
Globus Medical price target raised to $103 from $100 at BarclaysGlobus Medical price target raised to $103 from $100 at Barclays
Bank of America Securities
$97
Hold
31.69%
Upside
Reiterated
02/21/25
Analysts Offer Insights on Healthcare Companies: Insulet (NASDAQ: PODD), Globus Medical (NYSE: GMED) and Select Medical (NYSE: SEM)We didn’t get any surprises with GMED’s full Q4 results. Q4 revenue of $657m (+5.2% day adjusted) was inline with the preannouncement and GMED had reiterated its 2025 guidance only two weeks ago when it announced the Nevro acquisition. Musculoskeletal sales grew +4.5% y/y (+3.0% day adjusted) and enabling tech grew 44% and had another record quarter of placements. $0.83 beat the on lower tax rate and better net interest. EBITDA was 4% short of the Street because of Fx. The Nevro deal was the primary focus of the call. GMED shares are down 9% since the announcement two weeks ago.
Canaccord Genuity
$101
Buy
37.12%
Upside
Reiterated
02/20/25
Globus Medical's Promising Outlook: Strong Financials, Strategic Acquisitions, and Continued Innovation Drive 'Buy' Rating
Jefferies
$105
Buy
42.55%
Upside
Reiterated
02/06/25
Jefferies reiterates Buy Rating on Globus Medical (GMED)Jefferies analyst Matthew Taylor reiterated a Buy rating and $105.00 price target on Globus Medical (NYSE: GMED)
Oppenheimer
$73
Hold
-0.90%
Downside
Reiterated
08/14/24
Globus Medical (GMED) Receives a Hold from Oppenheimer
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Wells Fargo
Reiterated
03/24/25
Truist Financial
Reiterated
03/18/25
Stifel Nicolaus
Reiterated
03/18/25
Morgan Stanley
Reiterated
03/18/25
Needham
Reiterated
03/18/25
Piper Sandler
Reiterated
03/17/25
Roth MKM
Reiterated
03/13/25
RBC Capital
Reiterated
03/11/25
BTIG
Reiterated
02/24/25
JMP Securities
Reiterated
02/24/25
Barclays
$100→$103
Buy
39.83%
Upside
Reiterated
02/21/25
Globus Medical price target raised to $103 from $100 at BarclaysGlobus Medical price target raised to $103 from $100 at Barclays
Bank of America Securities
$97
Hold
31.69%
Upside
Reiterated
02/21/25
Analysts Offer Insights on Healthcare Companies: Insulet (NASDAQ: PODD), Globus Medical (NYSE: GMED) and Select Medical (NYSE: SEM)We didn’t get any surprises with GMED’s full Q4 results. Q4 revenue of $657m (+5.2% day adjusted) was inline with the preannouncement and GMED had reiterated its 2025 guidance only two weeks ago when it announced the Nevro acquisition. Musculoskeletal sales grew +4.5% y/y (+3.0% day adjusted) and enabling tech grew 44% and had another record quarter of placements. $0.83 beat the on lower tax rate and better net interest. EBITDA was 4% short of the Street because of Fx. The Nevro deal was the primary focus of the call. GMED shares are down 9% since the announcement two weeks ago.
Canaccord Genuity
$101
Buy
37.12%
Upside
Reiterated
02/20/25
Globus Medical's Promising Outlook: Strong Financials, Strategic Acquisitions, and Continued Innovation Drive 'Buy' Rating
Jefferies
$105
Buy
42.55%
Upside
Reiterated
02/06/25
Jefferies reiterates Buy Rating on Globus Medical (GMED)Jefferies analyst Matthew Taylor reiterated a Buy rating and $105.00 price target on Globus Medical (NYSE: GMED)
Oppenheimer
$73
Hold
-0.90%
Downside
Reiterated
08/14/24
Globus Medical (GMED) Receives a Hold from Oppenheimer
GMED Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
0
0
0
0
1
Buy
12
19
27
37
34
Hold
4
5
8
10
11
Sell
1
1
1
0
0
Strong Sell
0
0
0
0
0
total
17
25
36
47
46
Each month's total comprises the sum of three months' worth of ratings.
GMED Financial Forecast
GMED Stock Forecast FAQ
What is GMED’s average 12-month price target, according to analysts?
Based on analyst ratings, Globus Medical’s 12-month average price target is $98.75.
What is GMED’s upside potential, based on the analysts’ average price target?
Globus Medical has 34.06% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GMED a Buy, Sell or Hold?
Globus Medical has a consensus rating of Moderate Buy which is based on 10 buy ratings, 4 hold ratings and 0 sell ratings.
What is Globus Medical’s price target?
The average price target for Globus Medical is $98.75. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $115.00 ,the lowest forecast is $82.00. The average price target represents 34.06% Increase from the current price of $73.66.
The highest analyst price target is $115.00 ,the lowest forecast is $82.00. The average price target represents 34.06% Increase from the current price of $73.66.
What do analysts say about Globus Medical?
Globus Medical’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of GMED?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.